Dr. Stanley Ho Medical Development Foundation Symposium Jan 2014 Advances in the Management of Type 2 Diabetes Mellitus
|
|
- August Heath
- 6 years ago
- Views:
Transcription
1 Dr. Stanley Ho Medical Development Foundation Symposium Jan 2014 Advances in the Management of Type 2 Diabetes Mellitus Dr Ronald Ma Professor Dept of Medicine & Therapeutics Prince of Wales Hospital Chinese University of Hong Kong
2 Outline Update on Epidemiology of Type 2 diabetes Overview of current guidelines for T2DM Emerging new treatments Novel approach to DM complications Diabetes and cancer
3 A Real GDP per capita (USD) B. Prevalence (%) Diabetes In Asia India China Malaysia Singapore India China Malaysia Singapore Ramachandran A, Ma RC and Snehalatha DC, Lancet 2010; 375: Jan 30
4 Prevalence of DM in China 46,239 adults (> age of 20 years) 9.7% diabetes 15.5% Prediabetes 92.4 million DM 148.2m Prediabetes Yang W et al, NEJM 2010; March 25
5 Evolving Epidemic of Diabetes and Pre-diabetes Yang W et al, NEJM 2010; March 25 Xu et al, J Am Med Asso 2013; Sept 4
6 Heterogeneity of Diabetes in Asian populations Type 1 Type 2 Autoimmunity Monogenic DM?other causes T2 DM genes MODY Amylin gene mutations Mitochondrial DM LADA Metabolic syndrome Young-onset DM Only 10% of those with onset < 35 years have classical Type 1 DM 30-50% are insulin resistant In young-onset T2 DM, 10-15% carry either genetic or markers of insulin deficiency Anti-GAD present in 31% of T1DM, 11.8% of normal wt T2DM, 2.9% of obese T2DM Chan JC et al, JAMA 2009
7 Ectopic lipids Diet Obesity Physical inactivity Mitochondrial dysfunction Stress response Intrauterine env Aging Inflammation Insulin Resistance Diabetes Risk Changes in gene and protein function Type 2 Diabetes Insulin Secretion Genetics Epigenetic changes Gut microbiome Glucose sensing Incretins β-cell growth survival Adapted from Doria A et al, Cell Metab 2008
8 Outline Update on Epidemiology of Type 2 diabetes Overview of current guidelines for T2DM Emerging new treatments Novel approach to DM complications Other co-morbidities
9 Type 2 diabetes is a chronic condition with progressive loss of β-cell function over time UKPDS 16 Study β-cell function (% of normal by HOMA) ? ß-cell function = 50% of normal Time of diagnosis HOMA = homeostasis model assessment Holman RR, et al. Diab Res Clin Pract. 1998;40(Suppl):S21 S25. UKPDS Study Group. Diabetes. 1995;44: Years ~50% of ß cell function was already lost at the time of diagnosis in UKPDS
10 Most current therapies for type 2 diabetes promote weight gain UKPDS 34 Study Change in weight (kg) Years from randomization Conventional* (n=411) Glibenclamide (n=277) Metformin (n=342) Insulin (n=409) Up to 5 kg is already gained within just 3 years with a sulphonylurea or insulin *Diet initially then sulphonylureas, insulin and/or metformin if FPG>15 mmol/l UKPDS 34 Study. Lancet 1998:352:854 65
11 Pathogenesis of Hyperglycaemia in Type 2 DM insulin secretion Neurotransmitter dysfunction lipolysis HYPERGLYCAEMIA é Glucagon Secretion α-cells é Glucose resorption é Hepatic glucose production Incretin effect Glucose uptake Adapted from DeFronzo RA. Diabetes 2009; 58: 773
12 The incretins GLP-1 and GIP mediate glucose-stimulated insulin release Food intake Pancreas Glucose-dependent insulin secretion β-cells Increases glucose utilisation by muscle and adipose α-cells Glucose-dependent glucagon suppression Decreases hepatic glucose release Intestine Active GLP-1 (7-36) Active GIP Glucose homeostasis GLP-1 = Glucagon-like peptide-1, secreted from L-cells in the distal gut GIP = glucose-dependent insulinotropic peptide, secreted from K-cells in the proximal gut Adapted from Drucker DJ. Expert Opin Invest Drugs. 2003;12(1): Ahrén B. Curr Diab Rep. 2003;3:
13 Glucagon-like-peptide (GLP) -1 is degraded by DPP-4 Food intake Pancreas Glucose-dependent insulin secretion β-cells Increases glucose utilisation by muscle and adipose Glucose-dependent glucagon suppression Decreased hepatic glucose release improves overall glucose control α-cells Intestine Active GLP-1 (7-36) DPP-4 Inactive GLP-1 (9-36) amide DPP-4 = Dipeptidyl peptidase-4 His-Ala cleaved from amino terminus Adapted from Drucker DJ. Expert Opin Invest Drugs. 2003;12(1): Ahrén B. Curr Diab Rep. 2003;3:
14 Blocking DPP-4 can improve incretin activity and correct the insulin:glucagon ratio in T2DM T2DM Incretin response diminished Insulin Further impaired islet function Hyperglycaemia Glucagon DPP-4 inhibitor Insulin Incretin activity prolonged Improved islet function Improved glycaemic control Glucagon DPP-4=dipeptidyl peptidase-4; T2DM=type 2 diabetes mellitus. Adapted from Unger RH. Metabolism. 1974;23: ; Ahrén B. Curr Enzyme Inhib. 2005;1:65 73.
15 Oral glucose-lowering agents: An overview Effect on weight Risk of hypos Common adverse events Effect on insulin resistance Effect on insulin secretion Metformin x GI disorders DPP-4 inhibitors x Nasopharyngitis * Sulphonylureas Glinides Thiazolidinediones x Hypoglycemia, Weight gain Hypoglycemia Weight gain Weight gain, Fluid retention α-glucosidase inhibitors x GI discomfort * glucose-dependent Fonseca, V., et al. Diabetes Obes Metab Apr 11; DeFronzo RA. Ann Intern Med. 1999;131: ; UKPDS. Lancet. 1998; 352: ; Aschner P, et al. Diabetes Care.2006;29(12):2632-7; ADA and EASD Consensus statement. Diabetes Care. 2009;32: ; Nesto RW, et al. Circulation 2003;108: ; Matthaei S, et al. Endocrine Reviews. 2000;21: ; Raptis SA & Dimitriadis GD. J Exp Clin Endocrinol. 2001;109:S265 S287.
16 The ideal treatment regime for T2DM Effective lowering of blood glucose Minimal risk of hypoglycaemia Reduction of body weight or weight-neutral Preservation of beta-cell function Improvement in cardio-metabolic risk factors Minimal drug interaction Good safety profile in elderly patients Can be safely combined with other oral drugs or insulin Can reduce cardiovascular risk
17 Individualized ADA / EASD treatment Positional Statement for Type Diabetes Source: ADA / EASD position statement 2012 : Diabetes Care Publish Ahead of Print, published online April 19, 2012
18 DPP4-I: a reasonable OAD choice after metformin due to its safety & tolerability profile Source: ADA / EASD position statement 2012 : Diabetes Care Publish Ahead of Print, published online April 19, 2012
19 19
20 20 Presentation Title Presenter Name Date Subject Business Use Only
21 Approximately 40% of type 2 diabetes patients have renal complications CKD prevalence was greater among people with diabetes than among those without diabetes (40.2% versus 15.4%) Data missing no CKD CKD stage 1 CKD stage 2 CKD stage 3 CKD stage 4/5 CKD Stage egfr (ml/min) No CKD 90* 1 90** * Normal kidney function, no sign of kidney damage ** Albuminuria kidney damage 5 <15 or dialysis Based on data from 1462 patients aged 20 years with T2DM who participated in the Fourth National Health and Nutrition Examination Survey (NHANES IV) from 1999 to Koro CE, et al. Clin Ther. 2009;31: ; 2. Saydah S, et al. JAMA. 2007;297(16):1767.
22 Current treatments for type 2 diabetes have limitations when renal function declines Injectables Insulin Liraglutide Exenatide Dose Reduction Dose Reduction Linagliptin Sitagliptin Vildagliptin Saxagliptin Dose Reduction Dose Reduction Dose Reduction Oral drugs Metformin Acarbose Repaglinide Dose Reduction Glimepiride Gliclazide Pioglitazone Dose Reduction Dose Reduction > <30 Declining GFR Adapted from: Schernthaner G, et al. Nephrol Dial Transplant. 2011;26(2):454 7 (in press) and respective SmPCs Hemodialysis
23 DPP4-I: safe to use in patients with moderate to severe renal impairment Degree of renal impairment Vildagliptin Sitagliptin Saxagliptin Linagliptin Normal 50 mg QD or BID 100 mg QD 5 mg QD 5 mg QD Mild 50 mg QD or BID 100 mg QD 5 mg QD 5 mg QD Moderate 50 mg QD 50 mg QD 2.5 mg QD 5 mg QD Severe 50 mg QD 25 mg QD 2.5 mg QD 5 mg QD Prescribing information of vildagliptin, sitagliptin, saxagliptin & linagliptin
24 Hypoglycemia is a major concern in the elderly Patient risk factors Advanced age Recent hospitalization Intercurrent illness Chronic liver, renal or cardiovascular disease Endocrine deficiency (thyroid, adrenal, pituitary) Loss of normal counterregulation Lifestyle risk factors Poor nutrition or fasting Prolonged physical exercise Alcohol (ethanol) Drug risk factors Use of sulfonylureas or insulin Drug interactions with SUs Hypoglycemic unawareness SU=sulfonylurea. Adapted from Chelliah A, Burge MR. Drugs Aging. 2004; 21:
25 In this multinational, double-blind, 24 week study, drug-naive or inadequately controlled (HbA1c 7 & 10%) patients with T2DM aged 70 years or older were enrolled Investigators set individualised treatment targets on the basis of age, baseline HbA1c, comorbidities, and frailty status before a validated automated system randomly assigned patients (1:1) to vildagliptin (50 mg once or twice daily as per label) or placebo. Co-primary efficacy endpoints were proportion of patients reaching their investigatordefined HbA1c target HbA1c reduction from baseline to study end
26 Vildagliptin significantly reduced A1c in elderly patients without increasing AEs Hypoglycemia Vildagliptin Placebo Overall 2.2% 0.7% Severe hypoglycemia 0% 0%
27 Phenotypic heterogeneity of Diabetes in Asians Kong AP, et al, Nat Rev Endocrinol 2013; May 28 Ma RC and Chan JC. Ann N Y Acad Sci 2013; April Ramachandran A, Ma RC et al, Lancet 2010; 375: Chan JC et al, JAMA 2009; May 27
28 Meta-analysis of 55 DPP4I trials comparing effect in Asians and Non-Asians Combined difference in HbA1c -0.26% Efficacy correlated with baseline BMI Difference most marked for FBG Kim YG et al, Diabetologia 2013; 56:
29
30 Metformin and AcaRbose in Chinese as the initial Hypoglyacemic treatment (MARCH ) Trial -4w 0 24w 48 w Acarbose (N=391) N=351 Acarbose (N=326) Run-in N=942 Monotherapy Monotherapy or add-in therapy Metformin (N=393) N=347 Metformin (N=314) Mean HbA1c reduction at 48w: -1.11% acarbose vs -1.12% metformin Acarbose group lost more weight: -0.63kg (-1.15 to -0.10, p=0.0194) Acarbose group more favourable lipid profile Acarbose less postprandial hyperinsulinaemia Yang W et al, Lancet Diabetes Endocrinol 2013; 18 Oct
31 Metformin and AcaRbose in Chinese as the initial Hypoglyacemic treatment (MARCH ) Trial Yang W et al, Lancet Diabetes Endocrinol 2013; 18 Oct
32 Glucose Insulin Glucagon GLP-1
33 Meal ingestion Postprandial glucose excursion Hyperinsulinaemia Glucagon α- glucosidase distal intestinal absorption of carbohydrates Ma RC. Lancet Diabetes Endocrinol 2014; 2: 6-7
34 Meal ingestion ê VLDL synthesis ê TG ê Postprandial glucose excursion ê Hyperinsulinaemia ê Glucagon ACARBOSE α- glucosidase Delayed distal intestinal absorption of carbohydrates GLP-1 Delayed gastric emptying Decreased appetite Altered gut microbiome Weight loss Ma RC. Lancet Diabetes Endocrinol 2014; 2: 6-7
35 Targeting the kidney for treatment of hyperglycaemia SGLT 2 inhibitors Tahrani A et al, Lancet Diabetes Endocrinol 2013; 1:
36 Dapagliflozin Added to patients on MF 24 week study 546 patients No increase in hypo Beneficial wt loss Increase in genital infections Bailey C et al, Lancet 2010, June 26
37 Intensive insulin therapy in newly diagnosed T2 DM- Beneficial effects on beta-cell function Remission rate 1yr 382 patients with newly diagnosed T2 DM Randomized to insulin or OHA Treatment stopped after normoglycaemia 2 weeks 51.1% 44.9% 26.7% Weng J et al. Lancet 2008; 371:
38 Meta-analysis of short-term intensive insulin therapy in T2DM Kramer C et al, Lancet Diabetes Endorinol 2013; 1: 28-34
39 The Burden of CV Complications in DM The Hong Kong Diabetes Registry ( ) >7,000 DM patients Mean age: 56 years Mean duration of follow-up 6 years Death 10.1% (768) Coronary heart disease 6.7% (507) Cardiac failure 4.5% (340) Stroke 5.6% (422) End stage renal disease 10.5 (799) Cancer 5.4% (413) Composite events 32.9% (2492) Yang, et al. Arch Intern Med. 2008; Am J Cardiol. 2008; Diabetes Care. 2007; Diabetologia
40 Pathogenesis of cardio-renal complications in DM Visceral obesity Insulin resistance Hypertension Hyperglycaemia Dyslipidaemia/ FFA Adipokines Ang II AGEs Protein Kinase C Aldose reductase Oxidative stress Inflammation Cellular death Abnormal growth Fibrosis Endothelial dysfunction Low grade infections Loss of structure and function Ma RC and Chan JC, Annals NY Acad Sci 2013 Cardio-renal complications
41 How to lower CVD risk Reduce LDL-C to <1.8mmol/l (70mg/dL) (statins) Raised HDL-C levels to >1.0mmol/l (>40mg/dL) and lower TG to <1.7mmol/l (<150mg/dL) (fibrates) Reduce BP to <130/<80mmHg (ACEI/ARB, CCB) Lower glucose levels A-A1c B-BP C-Cholesterol (LDL)
42 Incretin pathways and cardiovascular system CV Effects CV risk factors Endothelial fx Atherosclerosis Ischaemia/ Reperfusion Glucose metab LV function Drucker D. Cell Metab. 2006;3: ; Nikolaidis L, et al. Circulation. 2004;109:962.
43 Safety observations so far are promising, therefore all DPP-4 compounds are currently involved in outcome studies No increased risk of CV events was observed in patients randomly treated with DPP-4 inhibitors DPP-4 inhibitor better Comparator better Total patients in analysis Primary endpoint Comments Linagliptin ,239 CV death, MI, stroke, hospitalisation due to angina pectoris Pre-specified/ independent adjudication Sitagliptin ,246 Med DRA terms for MACE No formal adjudication; Post-hoc analysis Vildagliptin ,988 Acute coronary syndrome, transient ischaemic attack, stroke, CV death Pre-specified/ Independent adjudication Saxagliptin ,607 MI, stroke, CV death Pre-specified/ Independent adjudication Alogliptin ,489 Non-fatal MI, non-fatal stroke, CV death Pre-specified/ Independent adjudication 1/8 1/4 1/ Risk ratio for major CV events Johansen O-E., et al. ADA 2011 Late breaker 30-LB; 2. Williams-Herman D, et al. BMC Endocr Disord. 2010;10:7. 3. Schweizer A, et al. Diabetes Obes Metab. 2010;12(6): ; 4. Frederich R, et al. Postgrad Med. 2010;122(3):16 27; 5. White et al. 2010, ADA Scientific Sessions. Abstract 391-PP
44 Design of SAVOR Study 16,492 patients with established CV disease (CVD) or multiple risk factors (MRF) and HbA1c levels of 6.5% to 12% were randomized (ITT analysis population) Saxagliptin (n=8,280) 0.5% never took study drug (n=40) 18.4% prematurely discontinued study drug (n=1,527) Placebo (n=8,212) 0.5% never took study drug (n=39) 20.8% prematurely discontinued study drug (n=1,705) 97.6% completed the study (n=8,078) 97.4% completed the study (n=7,998) MEDIAN FOLLOW-UP: 2.1 Years Scirica BM, et al. N Engl J Med. 2013; doi: /NEJMoa
45 Kaplan-Meier Rates of the Primary Composite Endpoint CV Death, MI, or Stroke 14 Pa8ents With Endpoints (%) HR 1.00; 95% CI, P<0.001 (NI) P=0.99 (superiority) Saxaglip8n: 7.3%* Rate/100 person- yrs 3.7 Placebo: 7.2%* Rate/100 person- yrs 3.7 Placebo Saxaglip8n Days *K- M event rates are presented a/er 2 yrs. HR: hazard ra8o; K- M: Kaplan- Meier; Pbo: placebo; Saxa: saxaglip8n Scirica BM, et al. N Engl J Med /NEJMoa
46 Secondary Composite Efficacy Endpoint: Individual Components 2-Year Event Rate Saxagliptin (n=8,280) Placebo (n=8,212) Hazard Ratio (95% CI) P-value CV death 269 (3.2%) 260 (2.9%) 1.03 ( ) 0.72 MI 265 (3.2%) 278 (3.4%) 0.95 ( ) 0.52 Ischemic stroke 157 (1.9%) 141 (1.7%) Endpoint 0.38 Hospitalization for HF 289 (3.5%) 228 (2.8%) 1.27 ( ) Hospitalization for coronary revascularization Hospitalization for unstable angina 423 (5.2%) 459 (5.6%) 0.91 ( ) (1.2%) 81 (1.0%) 1.19 ( ) 0.24 One component of the composite secondary endpoint, hospitalization for HF, occurred at a greater rate in the saxagliptin group compared with placebo. Among CV deaths, there was no imbalance in deaths due to HF (44 [0.5%] and 40 [0.5%] for saxagliptin and placebo, respectively). Scirica BM, et al. N Engl J Med. 2013; doi: /NEJMoa
47 Pancreatitis and Pancreatic Cancer Patients (%) Endpoint Saxagliptin (n=8,280) Placebo (n=8,212) P-value Any pancreatitis* 0.3% 0.3% 0.77 Acute (Definite or possible) 0.3% 0.2% 0.42 Acute (Definite) 0.2% 0.1% 0.17 Acute (Possible) 0.1% 0.1% 0.79 Chronic <0.1% 0.1% 0.18 Pancreatic cancer Independently adjudicated incidence of pancreatitis was similar with saxagliptin and placebo (0.3% for both; P=0.77). The observed rates of pancreatic cancer were lower in the saxagliptin group (5 patients) than in the placebo group (12 patients; P=0.095). *Patients may have had more than one type of event. Scirica BM, et al. N Engl J Med. 2013; doi: /NEJMoa
48 Outline Update on Epidemiology of Type 2 diabetes Overview of current guidelines for T2DM Emerging new treatments Novel approach to DM complications Diabetes and cancer
49 Diabetes and Cancer Seshasai et al, Emerging risk factors collaboration NEJM 2011
50 Hyperglycaemia and cancer risk Hong Kong Diabetes Registry Causes of death In 7000 T2D FU 6 years 1% A1c 18% HR for cancer So WY et al DMRR 2008 Yang XL et al Diabetes 2010
51 Inzucchi et.al. Diabetologia
52 Personalized Medicine in Diabetes Treatment selection should be based on patient characteristics: Age Body weight Complications Disease duration Pozzilli P.Del Prato S. Diab Metab Res Rev 2010
53 Summary Epidemic of diabetes with increasing proportion of young patients with diabetes Improved understanding of the pathogenesis of type 2 diabetes has led to several novel treatment strategies Therapies with complementary mechanisms of action should be used in combinations for optimum glycemic control Safety and efficacy should be given high priorities in the decision of choice of agents for the patient The A1c target must be individualized, based on numerous factors, such as age, co-morbid conditions, risk of hypoglycemia, adherence, etc.
GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationSitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist
Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationNovel anti-diabetic therapies
Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationWhat to add after metformin: primary care conference 2016
objectives What to add after metformin: primary care conference 216 Dr. Tsang Man Wo Specialist in Endocrinology, Diabetes & Metabolism Medical Director, United Medical Practice. Consultant (P), M+G department,
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationEvidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationGlycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationOral Anti-diabetic Drugs in Older Adults with Diabetes
Oral Anti-diabetic Drugs in Older Adults with Diabetes Jae Min Lee Division of Endocrinology-Metabolism, Department of Internal Medicine, Eulji University Hospital, Eulji University School of Medicine,
More informationMANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?
MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY? Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Staff Endocrinologist, St. Michael's Hospital Relationships with commercial
More informationMetabolic Karma. - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D
2014 ICDM Breakfast Symposium. Oct 18, 2014 Grand Hilton, Seoul Metabolic Karma - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D Department of Endocrinology and Metabolism, Hallym University
More informationExploring Non-Insulin Therapies in Type 1 Diabetes. Objectives. Pre-Assessment Question #1. Disclosures
Exploring Non-Insulin Therapies in Type 1 Diabetes Disclosures Dr. Cornell: Advanced Practitioner Advisory Board and Speakers Bureau: Novo Nordisk Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More information